The Oral Cancer Foundation is pleased to have developed partnerships with two highly visible Hollywood stars to raise awareness of a disease of which too few people in the U.S. have ever heard. Academy Award winning actor, Michael Douglas, who has recently completed successful treatment for an advanced oral cancer, and Emmy and Tony Award winning actress, Blythe Danner, who lost her husband to the same disease have partnered with OCF to send a very important message about screening and early detection of oral cancer to the American public.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57170-oral-cancer-foundation-michael-douglas-early-detection-psa-campaign
At its annual meeting of more than 10,000 financial representatives and staff members today, Northwestern Mutual announced its new multi-year philanthropic program to fight childhood cancer. The effort, through the Northwestern Mutual Foundation, builds upon the company’s legacy of helping children and families. It leverages Northwestern Mutual’s field force throughout the country to implement a range of community events and programs to raise awareness and money for pediatric cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53645-northwestern-mutual-philanthropic-campaign-pediatric-cancer-research
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
St. Jude Children’s Research Hospital is launching a new series of public service announcements (PSAs) to help raise awareness and deepen the understanding of the hospital’s lifesaving mission through real St. Jude heroes – its patients and families. St. Jude has not produced national PSAs since 2003 and timed this new multichannel campaign to coincide with the hospital’s 50th anniversary.
The PSAs share St. Jude moments through patients and families like 10-year-old Angiel. Angiel and her mom Damaris were planning a trip to Africa for a family reunion when she was diagnosed with osteosarcoma, a type of bone cancer that produced tumors in both of Angiel’s legs. Today, thanks to St. Jude doctors, Angiel can still look forward to visiting family in a foreign land one day. Angiel’s story is just one of several patients featured in the PSAs.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/stjude/46749/
Boehringer Ingelheim Pharmaceuticals, Inc. and CancerCare® today announced the launch of My Cancer Circle™ (www.MyCancerCircle.net), a free, private, customizable online tool that enables caregivers of people facing cancer to organize and coordinate a circle of family members and friends to provide practical and emotional support. MyCancerCircle.net will provide caregivers of people facing cancer a simple, effective answer to a question they are asked constantly, “What can we do to help?”
To view Multimedia News Release, go to http://www.multivu.com/mnr/56339-boehringer-ingelheim-cancercare-my-cancer-circle-online-tool-caregivers
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52993-st-jude-childrens-research-hospital-comprehensive-human-cancer-genome-data
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Kohl’s Department Stores (NYSE: KSS) announced today that in celebration of life, survival, and a “Wish for a World with Less Breast Cancer and More Birthdays,” Kohl’s threw a “One Wish” Birthday Bash at the 2012 American Cancer Society Making Strides Against Breast Cancer® walk, May 5, 2012, on Milwaukee’s lakefront. Decorated with nearly 8,000 pink cake pops, balloons and giant birthday candles, the celebration represents the company’s greater commitment to the fight against breast cancer. More than 3,000 Kohl’s associates, friends and family took part in the walk.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55012-kohl-s-one-wish-birthday-2012-making-strides-against-breast-cancer-walk
Bobby Hurley, former All-American guard at Duke and current assistant coach of the University of Rhode Island men’s basketball team, and Travis Ford, two-time SEC tournament MVP at Kentucky and current Oklahoma State University head coach, traded in their playbooks for chore lists at the “LG Home Court Challenge” during the NCAA® Final Four® weekend.
LG Electronics USA, an official Corporate Partner of the NCAA, hosted the competition and donated a total of $20,000 in the participating coaches’ names to Coaches vs. Cancer® and the MD Anderson Children’s Cancer Hospital.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54895-ncaa-coaches-face-off-lg-home-court-challenge-men-s-final-four-weekend
Nearly five black women die needlessly per day from breast cancer in the United States – a total of 1,722 deaths annually – according to a study released today at the Avon Foundation Breast Cancer Forum and simultaneously published in Cancer Epidemiology. The 2012 Racial Disparity in Breast Cancer Mortality Study found that 21 of the 25* largest U.S. cities have a black: white disparity in breast cancer mortality, 13 of which are statistically significant.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52895-avon-foundation-breast-cancer-forum-racial-disparity-mortality-study
